Social Capital Suvretta Holdings Corp. III (DNAC) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Social Capital Suvretta Holdings Corp. III (DNAC) Financial Services Profile

Social Capital Suvretta Holdings Corp. III (DNAC) is a Henderson, Nevada-based shell company, incorporated in 2021, operating within the Financial Services sector. It is dedicated to identifying and executing a business combination, specifically targeting companies in the biotechnology industry, with a focus on the organ space sub-sector, rather than conducting its own significant operations.

What Is the Investment Thesis for DNAC?

The investment thesis for Social Capital Suvretta Holdings Corp. III (DNAC) centers on its potential to execute a transformative business combination within a high-growth sector. As a shell company with a market capitalization of $2.16B, its current financial metrics, including a profit margin of -8418.0% and a gross margin of -224.4%, are reflective of its pre-operational status, where expenses are incurred without revenue generation. The primary value driver is the successful identification and acquisition of a promising private biotechnology company, specifically within the organ space sub-sector. This targeted approach aims to leverage the significant innovation and market potential within this specialized area of healthcare. Key growth catalysts include the announcement of a definitive merger agreement, which would validate the company's search efforts and provide clarity on its future operating business. The expertise and reputation of its leadership, Chamath Palihapitiya, are anticipated to attract high-quality target companies and instill investor confidence. The successful completion of a de-SPAC transaction would transition DNAC into an operating entity, unlocking potential for growth driven by the acquired company's product pipeline, market penetration, and strategic execution. Risks include the failure to identify a suitable target or complete a transaction within the stipulated timeframe, potential shareholder redemptions, and the inherent volatility of the biotechnology sector. The absence of a dividend yield underscores its focus on capital deployment for strategic growth rather than immediate shareholder returns.

Based on FMP financials and quantitative analysis

DNAC Key Highlights

• Market capitalization of $2.16B, reflecting investor expectations for a future business combination as a shell company.
• Profit Margin of -8418.0%, indicative of a pre-revenue, pre-operational entity incurring expenses without generating income.
• Gross Margin of -224.4%, consistent with a company that has no significant operations and therefore no cost of goods sold or revenue.
• No dividend yield, as the company is not generating profits and is focused on capital deployment for a merger.
• Incorporated in 2021, establishing its relatively recent formation and ongoing search for a target business.

Who Are DNAC's Competitors?

DNAC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DNAC's Key Strengths?

• Experienced leadership through its CEO, Chamath Palihapitiya, potentially attracting high-quality targets.
• Clear and specialized focus on the biotechnology industry and the organ space sub-sector.
• Substantial capital raised and held in trust, providing funding for a significant acquisition.
• Established as a publicly traded entity, offering a clear path to market for a target company.

What Are DNAC's Weaknesses?

• No significant operations or revenue generation, leading to negative profit and gross margins.
• Reliance on a single successful business combination for its operational future.
• Limited operational history as an independent entity beyond its shell company status.
• Potential for shareholder redemptions if an attractive deal is not identified or approved.

What Could Drive DNAC Stock Higher?

• Search for a suitable business combination target within the biotechnology industry's organ space sub-sector.
• Announcement of a definitive agreement for a merger or acquisition with a target company.
• Completion of the de-SPAC transaction and subsequent transformation into an operating entity.
• Due diligence and negotiation processes with potential target companies.

What Are the Key Risks for DNAC?

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to identify or successfully complete a business combination within the mandated timeframe.
• Market volatility and investor sentiment shifts impacting SPAC valuations and potential redemptions.
• Inability to secure shareholder approval for a proposed business combination.
• Intense competition from other SPACs and private equity firms for attractive biotechnology targets.

What Are the Growth Opportunities for DNAC?

• Growth opportunity 1: The most significant growth opportunity for Social Capital Suvretta Holdings Corp. III lies in the successful identification and completion of a merger or acquisition with a high-potential private biotechnology company operating in the organ space sub-sector. This event would transform DNAC from a non-operational shell company into an active, revenue-generating entity. The market size for organ-related biotechnologies, including regenerative medicine, transplantation solutions, and bio-engineered organs, is substantial and projected to grow, driven by aging populations and medical advancements. A successful combination would allow DNAC shareholders to participate in the future growth and innovation of the acquired operating business, with a timeline dependent on the deal's execution.
• Growth opportunity 2: By specifically focusing its search on the biotechnology industry and the organ space sub-sector, Social Capital Suvretta Holdings Corp. III positions itself to potentially acquire a company operating in a market characterized by significant innovation and unmet medical needs. The biotechnology sector, particularly specialized areas like organ regeneration and transplantation, often commands high valuations due to the potential for groundbreaking therapies and large addressable patient populations. This strategic focus aims to capitalize on long-term trends in healthcare, where advancements in biological sciences are continuously opening new therapeutic avenues, offering substantial growth prospects for the combined entity over a multi-year horizon.
• Growth opportunity 3: The involvement of Chamath Palihapitiya as CEO provides a distinct advantage in attracting high-quality target companies and investor confidence. Palihapitiya's track record and network within the investment and technology communities can enhance DNAC's ability to identify, evaluate, and secure favorable terms for a business combination. This leadership capital can be a critical differentiator in a competitive SPAC market, potentially leading to a more attractive de-SPAC transaction. The perceived expertise and strategic guidance from such leadership can also contribute to the post-merger success of the acquired company, driving value creation for shareholders over the medium to long term.
• Growth opportunity 4: For a private biotechnology company in the organ space, merging with Social Capital Suvretta Holdings Corp. III offers an efficient and potentially less arduous path to becoming a publicly traded entity compared to a traditional Initial Public Offering (IPO). This access to public markets provides the target company with enhanced capital-raising capabilities, increased visibility, and liquidity for its existing shareholders. The ability to offer this streamlined route can make DNAC a more attractive partner for innovative private companies seeking growth capital and broader market exposure, thereby increasing the pool of potential high-quality targets and accelerating the timeline for a successful combination.
• Growth opportunity 5: Following a successful de-SPAC transaction, the combined entity would shift its focus to executing its operational strategy and realizing the growth potential of the acquired biotechnology business. This includes advancing product pipelines, securing regulatory approvals, expanding market reach, and forming strategic partnerships within the organ space. The capital raised by DNAC would be deployed to fund research and development, clinical trials, and commercialization efforts, aiming to unlock significant value. The timeline for this value creation is typically long-term, contingent on the successful development and commercialization of the acquired company's technologies and products in a competitive and regulated market.

What Opportunities Does DNAC Have?

• Successful merger with a high-growth biotechnology company in the organ space sub-sector.
• Capitalization on significant innovation and unmet medical needs within the specialized organ space market.
• Potential for substantial shareholder value creation following a successful de-SPAC transaction.
• Offering an efficient pathway for private companies to access public markets and growth capital.

What Threats Does DNAC Face?

• Failure to identify or successfully complete a suitable business combination within the mandated timeframe.
• Increased competition from other SPACs, private equity, and venture capital for attractive biotechnology targets.
• Regulatory changes impacting the SPAC market or the biotechnology industry.
• Market volatility and shifts in investor sentiment impacting SPAC valuations and potential redemptions.

What Are DNAC's Competitive Advantages?

• The reputation and network of its sponsor and CEO, Chamath Palihapitiya, which can attract high-quality target companies.
• A highly specific and focused investment mandate on the biotechnology industry's organ space sub-sector, allowing for specialized expertise.
• The capital raised and held in trust, providing substantial funding for a significant acquisition.

What Does DNAC Do?

Social Capital Suvretta Holdings Corp. III, incorporated in 2021 and headquartered in Henderson, Nevada, operates within the Financial Services sector as a shell company. Unlike traditional operating businesses, Social Capital Suvretta Holdings Corp. III does not possess significant ongoing operations or generate revenue from commercial activities. Its foundational purpose is to serve as a Special Purpose Acquisition Company (SPAC), a publicly traded entity designed specifically to raise capital through an initial public offering with the sole intent of acquiring or merging with an existing private company. This mechanism provides an alternative route for private companies to access public markets, bypassing the traditional IPO process. The company's strategic focus is sharply defined: it intends to search for a target business operating within the dynamic biotechnology industry. More specifically, Social Capital Suvretta Holdings Corp. III has narrowed its acquisition criteria to companies operating within the "organ space" sub-sector of biotechnology. This specialized focus suggests an intent to capitalize on advancements in areas such as organ transplantation, regenerative medicine, bio-engineered organs, or related therapeutic and diagnostic technologies. The process involves identifying a suitable private company, conducting extensive due diligence, negotiating terms for a merger, capital stock exchange, asset acquisition, stock purchase, or similar business combination, and ultimately seeking shareholder approval for the proposed transaction. Upon successful completion of such a business combination, Social Capital Suvretta Holdings Corp. III would typically cease to exist as a shell company and transform into the operating entity of the acquired business, with its shares then representing ownership in the newly combined public company. This model positions the company as a facilitator of market access and growth for innovative private enterprises in a highly specialized and potentially high-growth segment of the healthcare industry.

What Products and Services Does DNAC Offer?

• Operates as a shell company with no significant ongoing commercial operations.
• Focuses on identifying and executing a business combination with one or more businesses.
• Specifically targets companies within the biotechnology industry.
• Narrows its search to the organ space sub-sector of biotechnology.
• Aims to effect a merger, capital stock exchange, asset acquisition, or stock purchase.
• Provides a potential pathway for private biotechnology companies to become publicly traded.
• Incorporated in 2021 and is based in Henderson, Nevada.

How Does DNAC Make Money?

• Raises capital from public investors through its initial public offering to fund future acquisitions.
• Identifies, evaluates, and negotiates with private companies for a potential business combination.
• Aims to complete a merger or acquisition, thereby transforming into an operating company.
• Seeks to generate shareholder value through the growth and success of the acquired operating business post-merger.

What Industry Does DNAC Operate In?

Social Capital Suvretta Holdings Corp. III operates within the "Shell Companies" industry, a specialized segment of the broader "Financial Services" sector. This industry is characterized by Special Purpose Acquisition Companies (SPACs) that raise capital from public investors to acquire a private company, thereby taking it public. The competitive landscape for SPACs involves other shell companies vying for attractive private targets, as well as traditional private equity firms and venture capitalists. DNAC differentiates itself through its explicit focus on the biotechnology industry, particularly the organ space sub-sector. This targeted approach aims to capitalize on the significant innovation and capital requirements prevalent in biotech, where companies often seek alternative routes to public markets. Market trends indicate a continued demand for capital by innovative private companies, especially in specialized healthcare niches, making the SPAC model a relevant financing vehicle. DNAC's positioning allows it to potentially become a conduit for growth-stage biotechnology companies in the organ space to access public market funding and expertise.

Who Are DNAC's Key Customers?

• Institutional and retail investors who purchase its shares, anticipating a successful business combination.
• Private biotechnology companies in the organ space sub-sector seeking to access public markets.
• Shareholders who hold equity in the combined entity following a successful de-SPAC transaction.

Company Profile

Social Capital Suvretta Holdings Corp. III operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Henderson, US. The company is led by CEO Chamath Palihapitiya.

F-Score 1/9Financial Health

Social Capital Suvretta Holdings Corp. III's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 38.78 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 7%Key Financial Metrics

Return on equity for Social Capital Suvretta Holdings Corp. III stands at 7.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -25.8%, the inverse of the P/E and a quick read on earnings relative to price.

DNAC Valuation & Market Position

With a $2.16B market cap, Social Capital Suvretta Holdings Corp. III sits in the mid-cap segment of the market. Relative to its peer group, DNAC's quantitative score of 50/100 is below the peer average of 67/100.

DNAC Financials

DNAC Latest News

No recent news available for DNAC.

DNAC Analyst Consensus

DNAC MoonshotScore

DNAC Financial Services Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources